<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">90027</article-id><article-id pub-id-type="doi">10.7554/eLife.90027</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.90027.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-178365"><name><surname>Heitmann</surname><given-names>Stewart</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3351-9514</contrib-id><email>s.heitmann@victorchang.edu.au</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107673"><name><surname>Vandenberg</surname><given-names>Jamie I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3859-3716</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-92897"><name><surname>Hill</surname><given-names>Adam P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03trvqr13</institution-id><institution>Victor Chang Cardiac Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Darlinghurst</named-content></addr-line><country>Australia</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales</institution></institution-wrap><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03trvqr13</institution-id><institution>Victor Chang Cardiac Research Institute Innovation Centre</institution></institution-wrap><addr-line><named-content content-type="city">Darlinghurst</named-content></addr-line><country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Huang</surname><given-names>Christopher L-H</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ajijola</surname><given-names>Olujimi A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>University of California, Los Angeles</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>12</month><year>2023</year></pub-date><volume>12</volume><elocation-id>RP90027</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-06-22"><day>22</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-06-07"><day>07</day><month>06</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.19.537441"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-08-21"><day>21</day><month>08</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90027.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-07"><day>07</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90027.2"/></event></pub-history><permissions><copyright-statement>© 2023, Heitmann et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Heitmann et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-90027-v1.pdf"/><abstract><p>Many classes of drugs can induce fatal cardiac arrhythmias by disrupting the electrophysiology of cardiomyocytes. Safety guidelines thus require all new drugs to be assessed for pro-arrhythmic risk prior to conducting human trials. The standard safety protocols primarily focus on drug blockade of the delayed-rectifier potassium current (<italic>I</italic><sub>Kr</sub>). Yet the risk is better assessed using four key ion currents (<italic>I</italic><sub>Kr</sub>, <italic>I</italic><sub>CaL</sub>, <italic>I</italic><sub>NaL</sub>, <italic>I</italic><sub>Ks</sub>). We simulated 100,000 phenotypically diverse cardiomyocytes to identify the underlying relationship between the blockade of those currents and the emergence of ectopic beats in the action potential. We call that relationship the axis of arrhythmia. It serves as a yardstick for quantifying the arrhythmogenic risk of any drug from its profile of multi-channel block alone. We tested it on 109 drugs and found that it predicted the clinical risk labels with an accuracy of 88.1–90.8%. Pharmacologists can use our method to assess the safety of novel drugs without resorting to animal testing or unwieldy computer simulations.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cardiotoxicity</kwd><kwd>arrhythmia</kwd><kwd>safety pharmacology</kwd><kwd>electrophysiology</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>app1182032</award-id><principal-award-recipient><name><surname>Heitmann</surname><given-names>Stewart</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>app1142623</award-id><principal-award-recipient><name><surname>Hill</surname><given-names>Adam P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009287</institution-id><institution>NSW Health</institution></institution-wrap></funding-source><award-id>Cardiovascular capacity building grant</award-id><principal-award-recipient><name><surname>Hill</surname><given-names>Adam P</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001220</institution-id><institution>Medical Advances Without Animals Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Heitmann</surname><given-names>Stewart</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel mathematical method for screening new drugs for pro-arrhythmic cardiotoxicity without using animals or costly drug-specific computer simulations is proposed.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Torsades des Pointes is a potentially lethal ventricular arrhythmia that can be induced by many classes of drugs. These include antibiotics, antipsychotics, antihistamines, chemotherapeutics, and anti-arrhythmics (<xref ref-type="bibr" rid="bib43">Yap and Camm, 2003</xref>). The majority of torsadogenic drugs block the hERG ion channel which carries the delayed-rectifier potassium current <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib41">Witchel, 2011</xref>). For this reason, international safety guidelines require hERG block to be assessed in living cells prior to conducting human trials (<xref ref-type="bibr" rid="bib14">ICH, 2005</xref>). However, the standard hERG assay is overly sensitive. It does not accommodate multi-channel effects which render some drugs safe despite blocking hERG (<xref ref-type="bibr" rid="bib25">Martin et al., 2004</xref>; <xref ref-type="bibr" rid="bib12">Hoffmann and Warner, 2006</xref>). Consequently, many useful drugs are prematurely abandoned during pre-clinical trials. The safety pharmacology community is actively pursuing new in vitro and in silico assays that improve accuracy by targeting multiple ion channels (<xref ref-type="bibr" rid="bib35">Pugsley et al., 2008</xref>; <xref ref-type="bibr" rid="bib3">Colatsky et al., 2016</xref>).</p><p>In silico assays use computational models of cardiomyocyte electrophysiology in place of a living cell (<xref ref-type="bibr" rid="bib26">Mirams et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">Lancaster and Sobie, 2016</xref>; <xref ref-type="bibr" rid="bib24">Mann et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Dutta et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Passini et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Ballouz et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>). Drug blockade (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) is simulated in the model (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) by attenuating the conductivity of the relevant ion currents. The conductance parameters are labeled <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>G</mml:mi></mml:mstyle></mml:math></inline-formula> by convention. The simulations can be repeated across a diverse range of cardiac phenotypes to ensure generality of the results (<xref ref-type="bibr" rid="bib2">Britton et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Ni et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Gong and Sobie, 2018</xref>). The individual phenotypes are constructed by randomizing the conductance parameters to mimic natural variation in ion channel expression. The method produces a population of cardiac action potentials (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Selected biomarkers within the action potentials are then statistically analyzed for drug-induced changes (e.g. <xref ref-type="bibr" rid="bib13">Hondeghem, 2005</xref>; <xref ref-type="bibr" rid="bib40">Varshneya et al., 2021</xref>). Contemporary research is largely concerned with improving those biomarkers.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Conceptual framework.</title><p>(<bold>A</bold>) Drugs simultaneously block multiple species of ion channels to differing degrees. The principal ion currents implicated in drug-induced Torsades des Pointes are <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. (<bold>B</bold>) Simplified circuit diagram of cardiomyocyte electrophysiology. Drug blockade is simulated by attenuating the ionic conductances <inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. Those parameters are also varied randomly to mimic individual differences in electrophysiology. (<bold>C</bold>) Simulated action potentials of phenotypically diverse cardiomyocytes. Early after-depolarizations (red) are biomarkers for Torsades des Pointes. Conventional in silico assays simulate the effect of drugs on cardiomyocytes on a case-by-case basis. Our method inverts the procedure by simulating cardiomyocytes in the absence of drugs and then inferring how drugs would behave.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig1-v1.tif"/></fig><p>Yet the main problem with the conventional approach is that it requires multitudes of computationally intensive simulations for every drug that is assessed. Pharmacology laboratories must invest heavily in specialist computing resources and expertise before they can apply the methods to their drugs. We propose a new approach that allows drugs to be assessed without conducting drug-specific simulations. The method is initiated by simulating a diverse population of cardiomyocytes in the absence of drugs. That simulation need only be done once. The drug-free population is then used to identify the principal relationship between ionic conductances and ectopic phenotypes. We call that relationship the <italic>axis of arrhythmia</italic> because it describes the principal pathway for transforming benign cardiomyocytes into ectopic cardiomyocytes. Thereafter, the axis serves as a yardstick for assessing the torsadogenic risk of drugs directly from their physiological signature of ion channel blockade alone.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>The action potentials of 100,000 randomized ventricular cardiomyocytes (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) were simulated using a variant of the O’Hara-Rudy model (<xref ref-type="bibr" rid="bib33">O’Hara et al., 2011</xref>) that was optimized for long QT syndrome (<xref ref-type="bibr" rid="bib24">Mann et al., 2016</xref>; <xref ref-type="bibr" rid="bib18">Krogh-Madsen et al., 2017</xref>). Early after-depolarizations were chosen as a biomarker for Torsades des Pointes. Cardiomyocytes that exhibited early after-depolarizations were classified as <italic>ectopic</italic> (red) and those that did not were classified as <italic>benign</italic> (gray).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Benign versus ectopic cardiac phenotypes.</title><p>(<bold>A</bold>) Simulated action potentials for cardiomyocytes with randomly scaled conductance parameters <inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. Myocytes that exhibited early after-depolarizations were classified as <italic>ectopic</italic> (red). Those that did not were classified as <italic>benign</italic> (gray). (<bold>B</bold>) Swarm plots of the conductance scalars on a logarithmic scale. Color indicates the classification of the myocyte (benign versus ectopic). (<bold>C</bold>) Two-dimensional slice of parameter space showing the relationship between ectopic and benign phenotypes in <inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> versus <inline-formula><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. The dashed line is the statistical decision boundary. <inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> were fixed at unity <inline-formula><mml:math id="inf14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>0</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. (<bold>D</bold>) Two-dimensional slice showing <inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> versus <inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. In this case <inline-formula><mml:math id="inf17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>0.46</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>−</mml:mo><mml:mn>2.3</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:math></inline-formula>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig2-v1.tif"/></fig><p>The four cardiac ion currents that we investigated <inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> have previously been implicated in torsadogenic risk (<xref ref-type="bibr" rid="bib4">Dutta et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>). The myocytes were constructed by re-scaling the conductance parameters <inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> with randomly selected multipliers that were drawn uniformly from a logarithmic scale (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The use of the logarithmic coordinate frame is crucial to our subsequent analysis.</p><p>The ectopic and benign phenotypes were clearly segregated in parameter space (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). Multivariate logistic regression was used to identify the linear boundary (dashed line) that best separated the two classes. We refer to it as the <italic>decision boundary</italic> following the conventions of classification statistics.</p><sec id="s2-1"><title>Decision boundary</title><p>The multivariate logistic regression equation,<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mfrac><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>CaL</mml:mtext></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mtext>CaL</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>Kr</mml:mtext></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mtext>Kr</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>NaL</mml:mtext></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mtext>NaL</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>Ks</mml:mtext></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mtext>Ks</mml:mtext></mml:msub><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>describes the log-odds of a cardiomyocyte being ectopic where <inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The decision boundary is the hyperplane in four-dimensional parameter space <inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> where <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>. <xref ref-type="fig" rid="fig2">Figure 2C and D</xref> shows the intersection of that hyperplane (dashed) with two-dimensional slices of parameter space. Although we illustrate the concept in two dimensions, the analysis itself is conducted in four dimensions.</p><p>Our estimates of the regression coefficients, <inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>6.416</mml:mn><mml:mo>±</mml:mo><mml:mn>0.059</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.509</mml:mn><mml:mo>±</mml:mo><mml:mn>0.024</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>2.471</mml:mn><mml:mo>±</mml:mo><mml:mn>0.024</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.847</mml:mn><mml:mo>±</mml:mo><mml:mn>0.012</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>1.724</mml:mn><mml:mo>±</mml:mo><mml:mn>0.018</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula>, were all statistically significant <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>. The reported confidence intervals represent ± 1 SE. The model itself was also significantly different from the null model, <inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>χ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>99995</mml:mn><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>100000</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>73900</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> <inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></sec><sec id="s2-2"><title>The action of drugs in logarithmic coordinates</title><p>Drugs attenuate the conductivity of ion channels in a multiplicative fashion. The conductance of the drugged channel is defined as<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mtext>drug</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mi>δ</mml:mi><mml:mo>×</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mtext>ion</mml:mtext></mml:msub></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>ion</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> is the baseline conductance of the ion channel and <inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>δ</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mstyle></mml:math></inline-formula> is the fractional conductance imposed by the drug. Logarithmic coordinates transform the action of drug blockade into an additive process,<disp-formula id="equ3"><mml:math id="m3"><mml:mrow><mml:mrow><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mtext>drug</mml:mtext></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mtext>ion</mml:mtext></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>which can be expressed with vector geometry (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We denote the action of a drug by the vector,<disp-formula id="equ4"><mml:math id="m4"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">A</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">{</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mtext>CaL</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mtext>Kr</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mtext>NaL</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mtext>Ks</mml:mtext></mml:msub><mml:mo fence="false" stretchy="false">}</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula></p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Quantifying drug risk with the axis of arrhythmia.</title><p>(<bold>A</bold>) The axis of arrhythmia runs orthogonally to the decision boundary. As such, it describes the shortest pathway to ectopy for any cardiomyocyte. The basis vector of the axis is labeled <inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">B</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. The action of the drug is labeled <inline-formula><mml:math id="inf38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">A</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. The arrhythmogenic component of the drug is obtained by projecting vector <inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">A</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> onto vector <inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">B</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. The length of the projection is our measure of drug risk. (<bold>B</bold>) The probability of ectopy along the axis of arrhythmia. The origin corresponds to the baseline cardiomyocyte. The distance from the origin corresponds to the risk score. Distance is measured in log units, using the same scale as panel A.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig3-v1.tif"/></fig><p>where <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The values of <inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>δ</mml:mi></mml:mstyle></mml:math></inline-formula> would ordinarily be obtained from patch clamp experiments. In our case, we calculated them from the published potencies of 109 drugs collated by <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>.</p></sec><sec id="s2-3"><title>Axis of arrhythmia</title><p>We define the axis of arrhythmia as a line that runs orthogonally to the decision boundary (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). It represents the shortest path for shifting any cardiomyocyte into the ectopic regime by modifying the conductances of its ion channels. The basis vector of the axis,<disp-formula id="equ5"><label>(2)</label><mml:math id="m5"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">{</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>CaL</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>Kr</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>NaL</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mtext>Ks</mml:mtext></mml:msub><mml:mo fence="false" stretchy="false">}</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>is defined by the coefficients of the regression equation.</p></sec><sec id="s2-4"><title>Drug risk metric</title><p>The arrhythmogenic component of a drug is obtained by projecting the action of the drug onto the axis of arrhythmia. The length of the projection is our metric of drug risk. Specifically,<disp-formula id="equ6"><label>(3)</label><mml:math id="m6"><mml:mrow><mml:mtext>risk</mml:mtext><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="bold">A</mml:mi></mml:mrow><mml:mo>⋅</mml:mo><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">A</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> is the action of the drug, <inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">B</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> is the basis vector of the axis of arrhythmia, and<disp-formula id="equ7"><mml:math id="m7"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="bold">A</mml:mi></mml:mrow><mml:mo>⋅</mml:mo><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="thickmathspace"/></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>is the dot product. The metric is normalized to the Euclidean length of <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">B</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, which is denoted <inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>. From our regression coefficients,<disp-formula id="equ8"><mml:math id="m8"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">{</mml:mo><mml:mn>2.509</mml:mn><mml:mo>,</mml:mo><mml:mo>−</mml:mo><mml:mn>2.471</mml:mn><mml:mo>,</mml:mo><mml:mn>0.847</mml:mn><mml:mo>,</mml:mo><mml:mo>−</mml:mo><mml:mn>1.724</mml:mn><mml:mo fence="false" stretchy="false">}</mml:mo></mml:mrow></mml:math></disp-formula></p><p>and <inline-formula><mml:math id="inf47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msqrt><mml:msubsup><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>%</mml:mtext><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:msqrt><mml:mo>=</mml:mo><mml:mn>4.01</mml:mn></mml:mstyle></mml:math></inline-formula>.</p></sec><sec id="s2-5"><title>Risk scores</title><p>According to our metric, drugs that shift the electrophysiology <italic>toward</italic> the ectopic region have <italic>positive</italic> scores, whereas drugs that shift it <italic>away</italic> from ectopy have <italic>negative</italic> scores. Drugs that do neither have scores near zero.</p></sec><sec id="s2-6"><title>The a priori probability of ectopy</title><p>The probability of ectopy along the axis of arrhythmia,<disp-formula id="equ9"><label>(4)</label><mml:math id="m9"><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>is obtained by rearranging <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> and substituting <inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. <xref ref-type="disp-formula" rid="equ9">Equation 4</xref> describes the a priori probability of a cardiomyocyte being ectopic, based on its proximity to the decision boundary (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The shallow slope of the profile reflects the uncertainty in fitting a linear boundary to the data, as seen in <xref ref-type="fig" rid="fig2">Figure 2C and D</xref>.</p></sec><sec id="s2-7"><title>Susceptibility in the natural population</title><p>Any given drug alters the electrophysiology of all cardiomyocytes to the same extent, but only some cardiomyocytes become ectopic. The most susceptible are those that are closest to the decision boundary. We calculated the proportion of the natural population that would be susceptible to a given drug by analyzing how the drug shifts the population density with respect to the decision boundary.</p><p>Following the methods of <xref ref-type="bibr" rid="bib38">Sobie, 2009</xref>, <xref ref-type="bibr" rid="bib36">Sadrieh et al., 2013</xref>, <xref ref-type="bibr" rid="bib31">Morotti and Grandi, 2017</xref>, <xref ref-type="bibr" rid="bib5">Gong and Sobie, 2018</xref>, we assumed that ion channel conductances varied independently and were log-normally distributed <inline-formula><mml:math id="inf49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>0.112</mml:mn><mml:mo>,</mml:mo><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.472</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. A log-normal distribution maps onto a normal distribution in logarithmic coordinates, by definition. The natural population in our parameter space is therefore a symmetric multivariate Gaussian density function (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In the absence of drugs, the natural population density in four dimensions is centered at the point <inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">O</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">{</mml:mo><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>μ</mml:mi><mml:mo fence="false" stretchy="false">}</mml:mo></mml:mstyle></mml:math></inline-formula>.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Susceptibility to a drug in the natural population.</title><p>(<bold>A</bold>) Natural variation in ion channel conductivity is represented by a symmetric Gaussian density function centered at point <inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="bold">O</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. In this example, a 10-fold dose of Ibutilide shifts the population by 1.44 units toward the ectopic region. The proportion of ectopic myocytes in the drugged population is 41.5% (red). (<bold>B</bold>) The relationship between the drug risk score and ectopy in the natural population. The drug risk score corresponds to position on the axis of arrhythmia. The shaded region is the a priori probability of ectopy along that axis (reproduced from <xref ref-type="fig" rid="fig3">Figure 3B</xref>). The Gaussian profile (thin gray line) is the natural population density centered at zero. The proportion of myocytes that are ectopic (heavy black line) is 0.93% at baseline. That proportion rises as the drug shifts the population density toward the decision boundary.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig4-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-90027-fig4-video1.mp4" id="fig4video1"><label>Figure 4—video 1.</label><caption><title>An animated version of this figure showing how the population density shifts as the risk score increases.</title></caption></media></fig-group><p>The proportion of myocytes that become ectopic depends on how far the population is shifted along the axis of arrhythmia according to the risk metric (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The proportion is calculated as the product of the a priori probability of the ectopy (<xref ref-type="disp-formula" rid="equ9">Equation 4</xref>) and the density of the drugged population (<xref ref-type="disp-formula" rid="equ16">Equation 6</xref>; Methods). For the case of 10× therapeutic dose of Ibutilide — which is a potent <inline-formula><mml:math id="inf52"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> blocker — the proportion of the natural population that is susceptible to drug-induced Torsades is 41.5% (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The size of the susceptible population is a monotonic function of the drug’s risk score, so the torsadogenic risk can be described using either terminology.</p></sec><sec id="s2-8"><title>Validation against known drugs</title><p>We used the Hill equation to reconstruct the drug-response profiles of <inline-formula><mml:math id="inf53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf54"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf55"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> from the half-maximal inhibitory concentrations <inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> of 109 drugs reported by <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>. They labeled the clinical risks according to the Credible Meds list of QT drugs (<xref ref-type="bibr" rid="bib42">Woosley et al., 2019</xref>). In that labeling scheme, Class 1 drugs carry a known torsadogenic risk; Class 2 drugs carry a possible risk; Class 3 drugs carry a risk but only in conjunction with other factors; Class 4 drugs have no evidence of risk at all. The reconstructed drug-response profiles, along with their corresponding risk scores, are provided in <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref> and plotted in <xref ref-type="supplementary-material" rid="table2sdata2">Table 2—source data 2</xref>.</p></sec><sec id="s2-9"><title>Cases of Ajmaline and Linezolid</title><p>Ajmaline (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, top) is an anti-arrhythmic drug that slows conduction by blocking the fast sodium current, <inline-formula><mml:math id="inf58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib15">Kiesecker et al., 2004</xref>). It also blocks <inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, which is the reason Ajmaline has a known risk (Class 1) of inducing Torsades. In comparison, Linezolid (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, bottom) is an antibacterial agent that has no clinical evidence of Torsades (Class 4) even though it too blocks <inline-formula><mml:math id="inf60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, albeit to a lesser extent than it blocks <inline-formula><mml:math id="inf61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. Indeed, the two drugs have nearly opposite effects on <inline-formula><mml:math id="inf62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf63"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, as can be seen in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cases of Ajmaline and Linezolid.</title><p>(<bold>A</bold>) Drug-response profiles of <inline-formula><mml:math id="inf64"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf65"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> relative to the therapeutic dose. Open circles highlight 25× therapeutic dose. For Ajmaline, <inline-formula><mml:math id="inf66"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.654</mml:mn></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf67"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.0986</mml:mn></mml:mstyle></mml:math></inline-formula> at 25× dose. For Linezolid, <inline-formula><mml:math id="inf68"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.067</mml:mn></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf69"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.437</mml:mn></mml:mstyle></mml:math></inline-formula> at 25× dose. Data for <inline-formula><mml:math id="inf70"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf71"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> were not available, so those channels were assumed to be unaffected by the drugs in both cases <inline-formula><mml:math id="inf72"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf73"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula> (<bold>B</bold>) The blocking action of Ajmaline and Linezolid at 25× dose. By definition, <inline-formula><mml:math id="inf74"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. (<bold>C</bold>) The corresponding risk scores for Ajmaline <inline-formula><mml:math id="inf75"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>+</mml:mo><mml:mn>1.16</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> and Linezolid <inline-formula><mml:math id="inf76"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.18</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> at that dose. (<bold>D</bold>) The drug-induced shifts of the natural population density along the axis of arrhythmia. The proportion of myocytes that are ectopic with 25× dose of Ajmaline is 26% (red), compared to only 0.0095% for Linezolid.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig5-v1.tif"/></fig><p>At 25× therapeutic dose, the blocking action of Ajmaline is written in vector notation as<disp-formula id="equ10"><mml:math id="m10"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">A</mml:mi></mml:mrow><mml:mrow><mml:mtext>Ajmaline</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">{</mml:mo><mml:mo>−</mml:mo><mml:mn>0.425</mml:mn><mml:mo>,</mml:mo><mml:mo>−</mml:mo><mml:mn>2.32</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo fence="false" stretchy="false">}</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Likewise, the blocking action of Linezolid is<disp-formula id="equ11"><mml:math id="m11"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold">A</mml:mi></mml:mrow><mml:mrow><mml:mtext>Linezolid</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">{</mml:mo><mml:mo>−</mml:mo><mml:mn>2.71</mml:mn><mml:mo>,</mml:mo><mml:mo>−</mml:mo><mml:mn>0.828</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo fence="false" stretchy="false">}</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The two drugs shift the electrophysiology in opposite directions along the axis of arrhythmia (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The corresponding risk scores are <inline-formula><mml:math id="inf77"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>+</mml:mo><mml:mn>1.16</mml:mn></mml:mstyle></mml:math></inline-formula> for Ajmaline and <inline-formula><mml:math id="inf78"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>−</mml:mo><mml:mn>1.18</mml:mn></mml:mstyle></mml:math></inline-formula> for Linezolid. The signs of the scores suggest that Ajmaline is pro-arrhythmic whereas Linezolid is not, which agrees with the clinical risk labels. Indeed, the sizable negative score for Linezolid suggests that it may actually have anti-arrhythmic properties.</p><p>The effect of both drugs on the natural population is shown in <xref ref-type="fig" rid="fig5">Figure 5D</xref>. Ajmaline shifts the population density by 1.16 units toward the ectopic regime, making 26% of the population susceptible to Torsades. Conversely, Linezolid shifts the population 1.18 units away from the ectopic regime, making only 0.0095% of the population susceptible, which is a substantial drop compared to the baseline rate of 0.93%.</p></sec><sec id="s2-10"><title>The effect of dosage on multi-channel block</title><p>The action of a drug subtly changes direction with dosage because of differing response rates for each ion channel. For example, Ajmaline (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, left) disproportionately blocks more <inline-formula><mml:math id="inf79"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> than <inline-formula><mml:math id="inf80"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> with increasing dosage. Its dose-dependent action thus follows a gentle arc in parameter space rather than a straight line (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, left). The effect is less pronounced for Propafenone (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, middle) which recruits the ion channels more uniformly. Nonetheless, its path is still not strictly linear (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, middle). Linezolid (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, right) follows a similar pattern to Ajmaline (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, left), but in the opposite direction. Of these three drugs, only Propafenone blocks <inline-formula><mml:math id="inf81"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and none block <inline-formula><mml:math id="inf82"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, hence their pathways in <inline-formula><mml:math id="inf83"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf84"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) are of little consequence. Nonetheless, the pathways of other drugs (gray traces) are often curvilinear in four dimensions (<inline-formula><mml:math id="inf85"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf86"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf87"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf88"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>). That curvature influences how these drugs project onto the axis of arrhythmia, hence the risk scores depend on dosage. The shifting scores reflect the changing balance of ionic currents that occur naturally with multi-channel drugs.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Effect of dose on multi-channel drug-block.</title><p>(<bold>A</bold>) The attenuation of <inline-formula><mml:math id="inf89"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf90"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf91"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf92"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for 1× to 30× therapeutic doses of Ajmaline, Propafenone, and Linezolid, respectively. The ion channels respond to dosage at differing rates. (<bold>B</bold>) The dose-dependent action of each drug in the parameter space of <inline-formula><mml:math id="inf93"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf94"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. The paths are curvilinear because of the differing response rates of the ion channels. For comparison, the gray traces are the pathways of all 109 drugs in the dataset. (<bold>C</bold>) The corresponding pathways in <inline-formula><mml:math id="inf95"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf96"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. Propafenone attenuates <inline-formula><mml:math id="inf97"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> but not <inline-formula><mml:math id="inf98"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. Neither Ajmaline nor Linezolid attenuate <inline-formula><mml:math id="inf99"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> or <inline-formula><mml:math id="inf100"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, but other drugs do (gray traces).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig6-v1.tif"/></fig></sec><sec id="s2-11"><title>Testing the risk metric</title><p>The metric was tested by scoring all 109 drugs over a range of doses and comparing the results to the clinical risk labels from Credible Meds. The clinical labels were lumped into two categories for this purpose: UNSAFE (Classes 1 and 2) versus SAFE (Classes 3 and 4). Drugs that scored above a given threshold <inline-formula><mml:math id="inf101"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mtext>risk</mml:mtext><mml:mo>&gt;</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> were predicted to be unsafe and those that scored below the threshold <inline-formula><mml:math id="inf102"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mtext>risk</mml:mtext><mml:mo>&lt;</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula> were predicted to be safe. The threshold was optimized for each dosage. For example, a classification accuracy of 90.8% was achieved for drugs at 25× dose using a scoring threshold of <inline-formula><mml:math id="inf103"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.195</mml:mn></mml:mstyle></mml:math></inline-formula> (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Torsadogenic risk for 109 drugs at 25× dose.</title><p>Colors indicate the clinical risk labels from Credible Meds. The drugs are sorted by the score returned by our risk metric (lower axis). The proportion of the natural population that would be susceptible to the drug is shown on the upper axis. Drugs to the right of the scoring threshold <inline-formula><mml:math id="inf104"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.195</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> were classified as unsafe and those to the left of it were classified as safe. Misclassified drugs are marked with a triangle and highlighted in bold. In this case, 90.8% of the drugs were correctly classified.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig7-v1.tif"/></fig><p>The procedure was repeated for doses ranging from 1× to 32×. The classification accuracy for all dosage levels was found to lay between 88.1% and 90.8% (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). The differences were primarily due to borderline cases, so we refrain from nominating any one dosage as being optimal. In comparison, the conventional hERG assay has an accuracy of 78.9% for the same dataset (<xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Optimal dosage.</title><p>(<bold>A</bold>) Classification accuracy for drugs assessed at a range of dosages. (<bold>B</bold>) Receiver operating characteristic (ROC) curve for drugs at 5× dose. (<bold>C</bold>) ROC curve for drugs at 25× dose. AUROC is area under the ROC curve. TPR is true positive rate. FPR is false positive rate. The false negative rate is 1-TPR.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-fig8-v1.tif"/></fig><p>From a safety perspective, the trade-off between false negatives and false positives can be tuned by adjusting the scoring threshold, <inline-formula><mml:math id="inf105"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>θ</mml:mi></mml:mstyle></mml:math></inline-formula>. This is illustrated by the receiver operating characteristic (ROC) curves (<xref ref-type="fig" rid="fig8">Figure 8B and C</xref>). In our case, there is little difference between the ROC curves for drugs assessed at 5× dose versus 25× dose. The areas under the respective ROC curves (AUROC) are nearly identical at 91.3% and 91.5%. The conventional hERG assay, in comparison, has an AUROC of <inline-formula><mml:math id="inf106"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>77</mml:mn><mml:mo>±</mml:mo><mml:mn>7</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mstyle></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib16">Kramer et al., 2013</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we have proposed a new metric of torsadogenic risk that is based on the axis of arrhythmia. The major benefit of the metric is that it can be applied to novel drugs without conducting new computer simulations. The drug-response profiles of four ion currents <inline-formula><mml:math id="inf107"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> are all that is needed to calculate the torsadogenic risk of the drug. The ion currents can be measured using standard patch clamp techniques and the risk metric can be calculated with pen and paper. This simplicity removes a technological hurdle to the adoption of computational assays in safety pharmacology.</p><sec id="s3-1"><title>Identifying the axis of arrhythmia</title><p>All of the simulations in the present study were conducted in the absence of drugs. The simulations were only needed to identify the axis of arrhythmia and do not need to be repeated when applying the metric. The axis encapsulates the principal relationship between ion channel blockade and the onset of early after-depolarizations. It represents the most potent combination of pro-arrhythmic block that is theoretically possible for any drug, averaged across all cardiomyocytes. As such, it serves as an ideal yardstick for measuring the arrhythmogenic risk of real drugs.</p><p>The assumption that the boundary is linear is crucial for generalizing the findings across all cardiomyocytes. It allows the effect of a drug to be analyzed independently of the individual cardiomyocytes. So even though a nonlinear decision boundary might fit some cardiomyocytes better, it would not be helpful because the drug analysis would then be patient specific — which is not the aim of population safety pharmacology.</p></sec><sec id="s3-2"><title>Susceptibility to drug-induced arrhythmia</title><p>Our method can also predict the proportion of the population that would be susceptible to a drug without explicitly simulating it. The analysis is possible because drug blockade and phenotypic diversity both operate on the same properties of ion channels. The two biological processes are therefore mathematically interchangeable. As such, the distribution of the drugged population can be inferred from the drug-free population by shifting it according to the drug’s risk score. The size of the susceptible population is a function of the risk score. So the torsadogenic risk can be reported either as a raw score or as a percentage of the population at risk.</p></sec><sec id="s3-3"><title>Comparison to conventional approaches</title><p>Conventional in silico safety assays are designed to apply the drug directly to simulated cardiomyocytes and then use biomarkers in the action potential to predict the torsadogenic risk. The biomarkers are typically optimized using a formal set of training drugs proposed by the comprehensive in vitro proarrhythmia assay (CiPA) initiative (<xref ref-type="bibr" rid="bib3">Colatsky et al., 2016</xref>). See <xref ref-type="bibr" rid="bib6">Grandi et al., 2018</xref>, for a review. The CiPA steering committee (<xref ref-type="bibr" rid="bib22">Li et al., 2019</xref>) recommends that the electrophysiology be simulated using the CiPAORdv1.0 variant of the O’Hara-Rudy model which incorporates the kinetics of drugs binding with the hERG channel (<xref ref-type="bibr" rid="bib21">Li et al., 2017</xref>). The recommended biomarker is qNet (<xref ref-type="bibr" rid="bib4">Dutta et al., 2017</xref>) which measures the net charge of six major ion currents <inline-formula><mml:math id="inf108"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>to</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>K1</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The clinical risks of the CiPA drugs (n=28) are labeled low, intermediate, or high. <italic>Low</italic> versus <italic>intermediate-or-high</italic> risk drugs were predicted with 84–95% accuracy using manual patch clamp techniques; or 93–100% accuracy using automated patch clamping (<xref ref-type="bibr" rid="bib22">Li et al., 2019</xref>). Whereas <italic>low-or-intermediate</italic> versus <italic>high</italic> risk drugs were predicted to 92–100% accuracy using manual patch clamp; or 88–98% using automated patch clamp (<xref ref-type="bibr" rid="bib22">Li et al., 2019</xref>). The measurement of the drug potencies is a source of considerable variability, which is exacerbated by the small number of test drugs (n=16). The prediction accuracy reported by <xref ref-type="bibr" rid="bib22">Li et al., 2019</xref>, is higher than our method, but the results cannot be compared directly because the risk labels are stratified very differently.</p><p><xref ref-type="bibr" rid="bib34">Passini et al., 2017</xref>, used a larger dataset (n=62) to obtain 89% accuracy at predicting Class 1 versus Class 2–4 torsadogenic risk labels from Credible Meds. The cardiomyocytes were simulated using the baseline O’Hara-Rudy model without dynamic drug-binding kinetics. The accuracy is within the range of our results, but it too uses a slightly different risk stratification scheme. They scored the risk independently of dosage by averaging the number of early after-depolarizations, weighted by the concentration of the drug (<xref ref-type="bibr" rid="bib34">Passini et al., 2017</xref>). We believe it is better to quantify the risk as a function of dosage, since even the most lethal drug is safe at zero dose.</p><p>The present study uses the same dataset (n=109) as <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>, who investigated a suite of biomarkers using a recalibrated O’Hara-Rudy model which also had revised gating kinetics for <inline-formula><mml:math id="inf109"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Na</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. Their best performing biomarker was qNet, which predicted Class 1–2 versus Class 3–4 torsadogenic risk with 92.7% accuracy. It exceeds our best result by approximately 2% on the same risk stratification scheme. <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>, increased the overall performance to 94.5% by combining the best biomarkers into a decision tree. Interestingly, early after-depolarizations proved to be their worst biomarker, with only 78.9% accuracy, which is quite different to our findings. We suspect that their method under-estimated the predictive power of early after-depolarizations by only exploring normal physiological limits where such events are rare.</p></sec><sec id="s3-4"><title>Comparison to MICE models</title><p>MICE models (<xref ref-type="bibr" rid="bib16">Kramer et al., 2013</xref>) are purely statistical. They use logistic regression to predict the torsadogenic risk of a drug directly from the half-maximal inhibitory concentrations <inline-formula><mml:math id="inf110"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for hERG, Cav1.2 and Nav1.5. <xref ref-type="bibr" rid="bib16">Kramer et al., 2013</xref>, trained six candidate models on a dataset of 55 drugs. Their best model predicted the clinical risk labels of the drugs with 90.9% accuracy using only the difference between hERG and Cav1.2. Specifically,<disp-formula id="equ12"><mml:math id="m12"><mml:mrow><mml:mrow><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mfrac><mml:mi>p</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mo>-</mml:mo><mml:mi>H</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf111"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>H</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>=</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for hERG and <inline-formula><mml:math id="inf112"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for Cav1.2. Their regression equation is strikingly similar to ours (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>) except that MICE models use <inline-formula><mml:math id="inf113"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for the predictor variables where we use <inline-formula><mml:math id="inf114"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The distinction is that the <inline-formula><mml:math id="inf115"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>β</mml:mi></mml:mstyle></mml:math></inline-formula> coefficients in the MICE model have no biophysical interpretation, whereas in our model they are the basis of the axis of arrhythmia (<xref ref-type="disp-formula" rid="equ5">Equation 2</xref>) and so represent the most potent combination of pro-arrhythmic channel blocks that is theoretically possible. Interestingly, the accuracy of the two models is nearly identical, albeit on different datasets.</p></sec><sec id="s3-5"><title>Comparison to Bnet</title><p>Bnet (<xref ref-type="bibr" rid="bib29">Mistry, 2018</xref>) is a simple linear model that predicts the torsadogenic risk of a drug directly from the net blockade of inward and outward ion currents. Notably,<disp-formula id="equ13"><mml:math id="m13"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi mathvariant="normal">j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi mathvariant="normal">D</mml:mi><mml:mrow><mml:mi mathvariant="normal">j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf116"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>R</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf117"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>D</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> represent the percentage block of the repolarizing currents <inline-formula><mml:math id="inf118"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>to</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> and the depolarizing currents <inline-formula><mml:math id="inf119"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Na</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>K1</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, respectively. Percentage block is akin to <inline-formula><mml:math id="inf120"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> in our model, but without the logarithmic transform. Bnet predicts the clinical risk labels of the CiPA validation drugs as accurately as the CiPAORdv1.0 model when adjusted for drug binding kinetics (<xref ref-type="bibr" rid="bib22">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Mistry, 2019</xref>; <xref ref-type="bibr" rid="bib7">Han et al., 2019</xref>). This has opened a debate between model complexity and biophysical realism in which proponents of biophysical models advocate their explanatory benefits (<xref ref-type="bibr" rid="bib20">Lancaster and Sobie, 2017</xref>), whereas proponents of simple models advocate their predictive power without the computational expense (<xref ref-type="bibr" rid="bib27">Mistry et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Mistry, 2017</xref>).</p></sec><sec id="s3-6"><title>Conclusion</title><p>Our approach resolves the debate between model complexity and biophysical realism by combining both approaches into the same enterprise. Complex biophysical models were used to identify the relationship between ion channels and torsadogenic risk — as it is best understood by theory. Those findings were then reduced to a simpler linear model that can be applied to novel drugs without recapitulating the complex computer simulations. The reduced model retains a biophysical description of multi-channel drug block, but only as far as necessary to predict the likelihood of early after-depolarizations. It does not reproduce the action potential itself. Our approach thus represents a convergence of biophysical and simple models which retains the essential biophysics while discarding the unnecessary details. We believe the benefits of this approach will accelerate the adoption of computational assays in safety pharmacology and ultimately reduce the burden of animal testing.</p></sec><sec id="s3-7"><title>Limitations</title><p>The method was evaluated using a dataset of drugs that were drawn from multiple sources and diverse experimental conditions (<xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>). It is known that such measurements differ prominently between laboratories and recording platforms (<xref ref-type="bibr" rid="bib17">Kramer et al., 2020</xref>). Some drugs in the dataset combined measurements from disparate experiments while others had missing values. Of all the drugs in the dataset, only 17 had a complete set of <inline-formula><mml:math id="inf121"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> values for <inline-formula><mml:math id="inf122"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf123"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf124"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf125"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>I</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. The accuracy of the predictions is therefore limited by the quality of the drug potency measurements.</p><p>The accuracy of the axis of arrhythmia is likewise limited by the quality of the biophysical model from which it is derived. The present study only investigated one particular variant of the ORd model (<xref ref-type="bibr" rid="bib33">O’Hara et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">Krogh-Madsen et al., 2017</xref>) paced at 1 Hz. Other models and pacing rates are likely to produce differing estimates of the axis.</p></sec></sec><sec id="s4" sec-type="methods"><title>Methods</title><p>The action potentials of human endocardial ventricular cardiomyocytes were simulated using a variant of the ORD11 model (<xref ref-type="bibr" rid="bib33">O’Hara et al., 2011</xref>) in which the maximal conductances of <inline-formula><mml:math id="inf126"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf127"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf128"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf129"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf130"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>P</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaCa</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf131"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>P</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaK</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> were re-scaled (<xref ref-type="table" rid="table1">Table 1</xref>) to better reproduce the clinical phenotypes of long QT syndrome (<xref ref-type="bibr" rid="bib24">Mann et al., 2016</xref>; <xref ref-type="bibr" rid="bib18">Krogh-Madsen et al., 2017</xref>). The source code for the ORD11 model (<xref ref-type="bibr" rid="bib33">O’Hara et al., 2011</xref>) was adapted to run in the Brain Dynamics Toolbox (<xref ref-type="bibr" rid="bib8">Heitmann et al., 2018</xref>; <xref ref-type="bibr" rid="bib9">Heitmann and Breakspear, 2022a</xref>). The adapted source code is publicly available (<xref ref-type="bibr" rid="bib11">Heitmann, 2023</xref>). The differential equations were integrated forward in time using the matlab ode15s solver with error tolerances AbsTol = 1e-3 and RelTol = 1e-6. The model was paced at 1 Hz with a stimulus of –70 mV and duration of 0.5 ms. All simulations were equilibrated for at least 1000 beats prior to analysis.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>The baseline scaling factors applied to the ORD11 model.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Maximal conductance</th><th align="left" valign="bottom">Multiplier</th></tr></thead><tbody><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf132"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula></td><td align="char" char="." valign="bottom">8.09</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf133"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1.17</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf134"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> (<inline-formula><mml:math id="inf135"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>P</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ca</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>)</td><td align="char" char="." valign="bottom">3.57</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf136"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>P</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaCa</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula></td><td align="char" char="." valign="bottom">3.05</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf137"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>P</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaK</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1.91</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf138"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1.7</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Classification of ectopic phenotypes</title><p>Blocks of four successive beats were analyzed to accommodate alternans. Cells were classified as ectopic if any of those four beats contained an early after-depolarization — as defined by any secondary peak that rose above –50 mV and was separated from other peaks by at least 100 ms. Cells that did not exhibit early after-depolarizations were classified as benign.</p></sec><sec id="s4-2"><title>Parameter domain</title><p>We chose the domain of parameter space <inline-formula><mml:math id="inf139"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>±</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> through trial and error. That domain is large enough to cover the ectopic region, but not so large as to be unduly influenced by biological extremes. The parameters span between 0.05 and 20 times their baseline value.</p></sec><sec id="s4-3"><title>Natural population density</title><p>Cell-to-cell variability was mimicked by scaling the conductances <inline-formula><mml:math id="inf140"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> by a random multiplier that was drawn from a log-normal distribution (<xref ref-type="bibr" rid="bib38">Sobie, 2009</xref>). The parameters of the distribution <inline-formula><mml:math id="inf141"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>=</mml:mo></mml:mrow><mml:mn>0.112</mml:mn><mml:mo>,</mml:mo><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.472</mml:mn></mml:mstyle></mml:math></inline-formula>) were chosen to give the multipliers a mean of 1 and standard deviation of 0.5. The spread was based on our experience with previous simulations (<xref ref-type="bibr" rid="bib36">Sadrieh et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Sadrieh et al., 2014</xref>; <xref ref-type="bibr" rid="bib1">Ballouz et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">TeBay et al., 2022</xref>). The ion channel species were assumed to vary independently.</p><p>By definition, the log-normal distribution maps onto the normal distribution under the logarithmic transform. The natural population is therefore represented in logarithmic parameter space by a symmetric multivariate normal distribution. Specifically,<disp-formula id="equ14"><mml:math id="m14"><mml:mrow><mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo>,</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi><mml:mo>,</mml:mo><mml:mi>z</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>w</mml:mi><mml:mo rspace="4.2pt" stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>f</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo rspace="4.2pt" stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>f</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>y</mml:mi><mml:mo rspace="4.2pt" stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mi>f</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>z</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where<disp-formula id="equ15"><label>(5)</label><mml:math id="m15"><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:msqrt><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:msqrt></mml:mfrac></mml:mstyle><mml:mspace width="thinmathspace"/><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mi>μ</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:math></disp-formula></p><p>is the univariate normal distribution.</p></sec><sec id="s4-4"><title>Joint probability</title><p>Rotational symmetry allowed the multivariate distribution to be projected onto the axis of arrhythmia as a univariate distribution. The probability of a cardiomyocyte in the natural population being ectopic is<disp-formula id="equ16"><label>(6)</label><mml:math id="m16"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mo>∫</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thickmathspace"/><mml:mi>d</mml:mi><mml:mi>x</mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf142"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> is the a priori probability of ectopy for that phenotype (<xref ref-type="disp-formula" rid="equ9">Equation 4</xref>) and <inline-formula><mml:math id="inf143"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> is the proportion of cells in the population with that phenotype (<xref ref-type="disp-formula" rid="equ15">Equation 5</xref>). Drugs serve to shift <inline-formula><mml:math id="inf144"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> along the axis of arrhythmia. The size of that shift is defined by the risk metric (<xref ref-type="disp-formula" rid="equ6">Equation 3</xref>).</p></sec><sec id="s4-5"><title>Drug dataset</title><p>The drug-response curves were reconstructed using the Hill equation,<disp-formula id="equ17"><label>(7)</label><mml:math id="m17"><mml:mi>δ</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow><mml:mi>h</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mtext>IC</mml:mtext><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow><mml:mi>h</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>C</mml:mi><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mi>h</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf145"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>δ</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mstyle></mml:math></inline-formula> represents the fractional conductance of the ion channel. The concentration of the drug <inline-formula><mml:math id="inf146"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> was normalized to the effective free therapeutic plasma concentration (EFTPC). The EFTPCs and half-maximal inhibitory concentrations <inline-formula><mml:math id="inf147"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> were taken from Supplementary Table S2 of <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>, which was curated from publicly available datasets and scientific publications. Where multiple values were encountered, <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>, used the median <inline-formula><mml:math id="inf148"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and the worst-case (highest) EFTPC values. We assumed that ion channels with missing <inline-formula><mml:math id="inf149"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mtext>IC</mml:mtext><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> values were not blocked by the drug <inline-formula><mml:math id="inf150"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>δ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. We also fixed the Hill coefficients at <inline-formula><mml:math id="inf151"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>h</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:math></inline-formula> because (i) there is no evidence for co-operative drug binding in the literature, and thus no theoretical justification for using coefficients other than one; (ii) only 17 of the 109 drugs in the dataset had a complete set of Hill coefficients <inline-formula><mml:math id="inf152"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>CaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>NaL</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mtext>Ks</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> anyway. The clinical risk labels for the drugs were transcribed from Table 1 of <xref ref-type="bibr" rid="bib23">Llopis-Lorente et al., 2020</xref>.</p></sec><sec id="s4-6"><title>Dataset availability</title><p>The dataset containing the reconstructed drug-response curves is included in the source data for <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>The drug-response dataset.</title><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>The data in CSV format.</title></caption><media mimetype="application" mime-subtype="octet-stream" xlink:href="elife-90027-table2-data1-v1.csv"/></supplementary-material><supplementary-material id="table2sdata2"><label>Table 2—source data 2.</label><caption><title>Dose-response plots for each drug in the dataset.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-90027-table2-data2-v1.pdf"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variable name</th><th align="left" valign="bottom">Description</th></tr></thead><tbody><tr><td align="left" valign="bottom">DrugID</td><td align="left" valign="bottom">Unique identifier for each compound in the dataset</td></tr><tr><td align="left" valign="bottom">Compound</td><td align="left" valign="bottom">Name of the compound</td></tr><tr><td align="left" valign="bottom">Class</td><td align="left" valign="bottom">Clinical risk label where 1=<italic>known</italic> risk, 2=<italic>possible</italic> risk, 3=<italic>conditional</italic> risk, 4=<italic>no evidence of risk</italic></td></tr><tr><td align="left" valign="bottom">EFTPC</td><td align="left" valign="bottom">Effective free therapeutic plasma concentration (nM)</td></tr><tr><td align="left" valign="bottom">Cmax</td><td align="left" valign="bottom">Concentration relative to therapeutic dose</td></tr><tr><td align="left" valign="bottom">Conc</td><td align="left" valign="bottom">Concentration of the dose (nM)</td></tr><tr><td align="left" valign="bottom">GKrScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf153"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for the given dose (<xref ref-type="disp-formula" rid="equ17">Equation 7</xref>)</td></tr><tr><td align="left" valign="bottom">GNaScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf154"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for the given dose (<xref ref-type="disp-formula" rid="equ17">Equation 7</xref>)</td></tr><tr><td align="left" valign="bottom">GNaLScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf155"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for the given dose (<xref ref-type="disp-formula" rid="equ17">Equation 7</xref>)</td></tr><tr><td align="left" valign="bottom">GCaLScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf156"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for the given dose (<xref ref-type="disp-formula" rid="equ17">Equation 7</xref>)</td></tr><tr><td align="left" valign="bottom">GKsScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf157"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for the given dose (<xref ref-type="disp-formula" rid="equ17">Equation 7</xref>)</td></tr><tr><td align="left" valign="bottom">GK1Scale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf158"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for the given dose (<xref ref-type="disp-formula" rid="equ17">Equation 7</xref>)</td></tr><tr><td align="left" valign="bottom">GtoScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf159"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>t</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> for the given dose (<xref ref-type="disp-formula" rid="equ17">Equation 7</xref>)</td></tr><tr><td align="left" valign="bottom">LogGKrScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf160"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><inline-formula><mml:math id="inf161"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">LogGNaLScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf162"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">LogGCaLScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf163"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">LogGKsScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf164"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">LogGK1Scale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf165"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>K</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">LogGtoScale</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf166"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>α</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>t</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>t</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom">Score</td><td align="left" valign="bottom">Risk score (<xref ref-type="disp-formula" rid="equ6">Equation 3</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="s4-7"><title>Source code availability</title><p>The source code for the cell model is available from <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/7796721">https://zenodo.org/records/7796721</ext-link> under the GNU General Public License v3.0. The cell model requires version 2022 or later of the Brain Dynamics Toolbox (<xref ref-type="bibr" rid="bib9">Heitmann and Breakspear, 2022a</xref>) which can be downloaded from <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/7070703">https://zenodo.org/records/7070703</ext-link> under the BSD 2-clause license.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing - review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-90027-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The drug dataset used in this study is included in the source data for Table 2. The source code for the cell model is available from <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/7796721">https://zenodo.org/records/7796721</ext-link> (<xref ref-type="bibr" rid="bib11">Heitmann, 2023</xref>) under the GNU General Public License v3.0. The cell model requires version 2022 or later of the Brain Dynamics Toolbox (<xref ref-type="bibr" rid="bib9">Heitmann and Breakspear, 2022a</xref>) which can be downloaded from <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/7070703">https://zenodo.org/records/7070703</ext-link> ( <xref ref-type="bibr" rid="bib10">Heitmann and Breakspear, 2022b</xref>) under the BSD 2-clause license.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This study was supported by Australian NHMRC grants app1182032, app1182623, and NSW Health cardiovascular capacity building grant. SH was funded by The Medical Advances Without Animals Trust (MAWA) which aims to advance medical science and improve human health and therapeutic interventions without the use of animals or animal products. The Katana computing cluster on which the simulations were conducted is supported by Research Technology Services at UNSW Sydney.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballouz</surname><given-names>S</given-names></name><name><surname>Mangala</surname><given-names>MM</given-names></name><name><surname>Perry</surname><given-names>MD</given-names></name><name><surname>Heitmann</surname><given-names>S</given-names></name><name><surname>Gillis</surname><given-names>JA</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Co-expression of calcium and hERG potassium channels reduces the incidence of proarrhythmic events</article-title><source>Cardiovascular Research</source><volume>117</volume><fpage>2216</fpage><lpage>2227</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvaa280</pub-id><pub-id pub-id-type="pmid">33002116</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britton</surname><given-names>OJ</given-names></name><name><surname>Bueno-Orovio</surname><given-names>A</given-names></name><name><surname>Van Ammel</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>HR</given-names></name><name><surname>Towart</surname><given-names>R</given-names></name><name><surname>Gallacher</surname><given-names>DJ</given-names></name><name><surname>Rodriguez</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology</article-title><source>PNAS</source><volume>110</volume><fpage>E2098</fpage><lpage>E2105</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304382110</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colatsky</surname><given-names>T</given-names></name><name><surname>Fermini</surname><given-names>B</given-names></name><name><surname>Gintant</surname><given-names>G</given-names></name><name><surname>Pierson</surname><given-names>JB</given-names></name><name><surname>Sager</surname><given-names>P</given-names></name><name><surname>Sekino</surname><given-names>Y</given-names></name><name><surname>Strauss</surname><given-names>DG</given-names></name><name><surname>Stockbridge</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The comprehensive in vitro proarrhythmia assay (CiPA) initiative - update on progress</article-title><source>Journal of Pharmacological and Toxicological Methods</source><volume>81</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.vascn.2016.06.002</pub-id><pub-id pub-id-type="pmid">27282641</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Beattie</surname><given-names>KA</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>PN</given-names></name><name><surname>Wu</surname><given-names>WW</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Strauss</surname><given-names>DG</given-names></name><name><surname>Colatsky</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Optimization of an <italic>In silico</italic> cardiac cell model for proarrhythmia risk assessment</article-title><source>Frontiers in Physiology</source><volume>8</volume><elocation-id>616</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2017.00616</pub-id><pub-id pub-id-type="pmid">28878692</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>JQX</given-names></name><name><surname>Sobie</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Population-based mechanistic modeling allows for quantitative predictions of drug responses across cell types</article-title><source>NPJ Systems Biology and Applications</source><volume>4</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1038/s41540-018-0047-2</pub-id><pub-id pub-id-type="pmid">29507757</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>E</given-names></name><name><surname>Morotti</surname><given-names>S</given-names></name><name><surname>Pueyo</surname><given-names>E</given-names></name><name><surname>Rodriguez</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Safety pharmacology - risk assessment qt interval prolongation and beyond</article-title><source>Frontiers Research Topics</source><volume>1</volume><elocation-id>539</elocation-id><pub-id pub-id-type="doi">10.3389/978-2-88945-539-3</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Lee</surname><given-names>HA</given-names></name><name><surname>Yim</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Usefulness of bnet, a simple linear metric in discerning torsades de pointes risks in 28 CiPA Drugs</article-title><source>Frontiers in Pharmacology</source><volume>10</volume><elocation-id>1419</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01419</pub-id><pub-id pub-id-type="pmid">31849669</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitmann</surname><given-names>S</given-names></name><name><surname>Aburn</surname><given-names>MJ</given-names></name><name><surname>Breakspear</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The brain dynamics toolbox for matlab</article-title><source>Neurocomputing</source><volume>315</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.neucom.2018.06.026</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Heitmann</surname><given-names>S</given-names></name><name><surname>Breakspear</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022a</year><source>Handbook for the Brain Dynamics Toolbox: Version 2022</source><publisher-name>bdtoolbox.org</publisher-name></element-citation></ref><ref id="bib10"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Heitmann</surname><given-names>S</given-names></name><name><surname>Breakspear</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022b</year><data-title>Brain Dynamics Toolbox</data-title><version designator="Version 2022b">Version 2022b</version><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.5625923">https://doi.org/10.5281/zenodo.5625923</ext-link></element-citation></ref><ref id="bib11"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Heitmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Source code for Simulating the O’Hara-Rudy (ord) model of the human cardiac action potential in the brain Dynamics Toolbox</data-title><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7796720">https://doi.org/10.5281/zenodo.7796720</ext-link></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Warner</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends</article-title><source>Journal of Pharmacological and Toxicological Methods</source><volume>53</volume><fpage>87</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.vascn.2005.07.003</pub-id><pub-id pub-id-type="pmid">16289936</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hondeghem</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2005">2005</year><chapter-title>Triad: foundation for Proarrhythmia (Triangulation, reverse use dependence and instability)</chapter-title><person-group person-group-type="editor"><name><surname>Hondeghem</surname><given-names>LM</given-names></name></person-group><source>The hERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome</source><publisher-name>John Wiley &amp; Sons, Ltd</publisher-name><fpage>235</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1002/047002142X</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="confproc"><person-group person-group-type="author"><collab>ICH</collab></person-group><year iso-8601-date="2005">2005</year><article-title>The non-clinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals S7B</article-title><conf-name>International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use</conf-name></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiesecker</surname><given-names>C</given-names></name><name><surname>Zitron</surname><given-names>E</given-names></name><name><surname>Lück</surname><given-names>S</given-names></name><name><surname>Bloehs</surname><given-names>R</given-names></name><name><surname>Scholz</surname><given-names>EP</given-names></name><name><surname>Kathöfer</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Kreye</surname><given-names>VAW</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name><name><surname>Schoels</surname><given-names>W</given-names></name><name><surname>Karle</surname><given-names>CA</given-names></name><name><surname>Kiehn</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action</article-title><source>Naunyn-Schmiedeberg’s Archives of Pharmacology</source><volume>370</volume><fpage>423</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1007/s00210-004-0976-8</pub-id><pub-id pub-id-type="pmid">15599706</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Obejero-Paz</surname><given-names>CA</given-names></name><name><surname>Myatt</surname><given-names>G</given-names></name><name><surname>Kuryshev</surname><given-names>YA</given-names></name><name><surname>Bruening-Wright</surname><given-names>A</given-names></name><name><surname>Verducci</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MICE models: superior to the HERG model in predicting Torsade de Pointes</article-title><source>Scientific Reports</source><volume>3</volume><elocation-id>2100</elocation-id><pub-id pub-id-type="doi">10.1038/srep02100</pub-id><pub-id pub-id-type="pmid">23812503</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Himmel</surname><given-names>HM</given-names></name><name><surname>Lindqvist</surname><given-names>A</given-names></name><name><surname>Stoelzle-Feix</surname><given-names>S</given-names></name><name><surname>Chaudhary</surname><given-names>KW</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Bohme</surname><given-names>GA</given-names></name><name><surname>Bridgland-Taylor</surname><given-names>M</given-names></name><name><surname>Hebeisen</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Renganathan</surname><given-names>M</given-names></name><name><surname>Imredy</surname><given-names>J</given-names></name><name><surname>Humphries</surname><given-names>ESA</given-names></name><name><surname>Brinkwirth</surname><given-names>N</given-names></name><name><surname>Strassmaier</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>A</given-names></name><name><surname>Danker</surname><given-names>T</given-names></name><name><surname>Vanoye</surname><given-names>C</given-names></name><name><surname>Polonchuk</surname><given-names>L</given-names></name><name><surname>Fermini</surname><given-names>B</given-names></name><name><surname>Pierson</surname><given-names>JB</given-names></name><name><surname>Gintant</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>5627</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-62344-w</pub-id><pub-id pub-id-type="pmid">32221320</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krogh-Madsen</surname><given-names>T</given-names></name><name><surname>Jacobson</surname><given-names>AF</given-names></name><name><surname>Ortega</surname><given-names>FA</given-names></name><name><surname>Christini</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Global optimization of ventricular myocyte model to multi-variable objective improves predictions of drug-induced torsades de pointes</article-title><source>Frontiers in Physiology</source><volume>8</volume><elocation-id>1059</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2017.01059</pub-id><pub-id pub-id-type="pmid">29311985</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>MC</given-names></name><name><surname>Sobie</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Improved prediction of drug‐induced torsades de pointes through simulations of dynamics and machine learning algorithms</article-title><source>Clinical Pharmacology &amp; Therapeutics</source><volume>100</volume><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1002/cpt.367</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>MC</given-names></name><name><surname>Sobie</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Response to “complexity vs. simplicity: the winner is?” mechanism-based classifiers provide more than just classification</article-title><source>Clinical Pharmacology and Therapeutics</source><volume>101</volume><elocation-id>327</elocation-id><pub-id pub-id-type="doi">10.1002/cpt.500</pub-id><pub-id pub-id-type="pmid">27618710</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>PN</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Mdluli</surname><given-names>T</given-names></name><name><surname>Strauss</surname><given-names>DG</given-names></name><name><surname>Colatsky</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Improving the in silico assessment of proarrhythmia risk by combining herg (human ether-à-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology</article-title><source>Circulation. Arrhythmia and Electrophysiology</source><volume>10</volume><elocation-id>e004628</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCEP.116.004628</pub-id><pub-id pub-id-type="pmid">28202629</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ridder</surname><given-names>BJ</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>WW</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>PN</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Randolph</surname><given-names>A</given-names></name><name><surname>Johnstone</surname><given-names>RH</given-names></name><name><surname>Mirams</surname><given-names>GR</given-names></name><name><surname>Kuryshev</surname><given-names>Y</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Crumb</surname><given-names>WJ</given-names></name><name><surname>Strauss</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA Initiative</article-title><source>Clinical Pharmacology and Therapeutics</source><volume>105</volume><fpage>466</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1002/cpt.1184</pub-id><pub-id pub-id-type="pmid">30151907</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llopis-Lorente</surname><given-names>J</given-names></name><name><surname>Gomis-Tena</surname><given-names>J</given-names></name><name><surname>Cano</surname><given-names>J</given-names></name><name><surname>Romero</surname><given-names>L</given-names></name><name><surname>Saiz</surname><given-names>J</given-names></name><name><surname>Trenor</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>In silico classifiers for the assessment of drug proarrhythmicity</article-title><source>Journal of Chemical Information and Modeling</source><volume>60</volume><fpage>5172</fpage><lpage>5187</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.0c00201</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>SA</given-names></name><name><surname>Imtiaz</surname><given-names>M</given-names></name><name><surname>Winbo</surname><given-names>A</given-names></name><name><surname>Rydberg</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>MD</given-names></name><name><surname>Couderc</surname><given-names>JP</given-names></name><name><surname>Polonsky</surname><given-names>B</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>100</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.09.011</pub-id><pub-id pub-id-type="pmid">27663173</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>RL</given-names></name><name><surname>McDermott</surname><given-names>JS</given-names></name><name><surname>Salmen</surname><given-names>HJ</given-names></name><name><surname>Palmatier</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>BF</given-names></name><name><surname>Gintant</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block</article-title><source>Journal of Cardiovascular Pharmacology</source><volume>43</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1097/00005344-200403000-00007</pub-id><pub-id pub-id-type="pmid">15076220</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirams</surname><given-names>GR</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Fink</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Heath</surname><given-names>BM</given-names></name><name><surname>McMahon</surname><given-names>NC</given-names></name><name><surname>Gavaghan</surname><given-names>DJ</given-names></name><name><surname>Noble</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk</article-title><source>Cardiovascular Research</source><volume>91</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvr044</pub-id><pub-id pub-id-type="pmid">21300721</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>HB</given-names></name><name><surname>Davies</surname><given-names>MR</given-names></name><name><surname>Di Veroli</surname><given-names>GY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment</article-title><source>Frontiers in Pharmacology</source><volume>6</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2015.00059</pub-id><pub-id pub-id-type="pmid">25852560</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>HB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Complexity vs. simplicity: the winner is?</article-title><source>Clinical Pharmacology and Therapeutics</source><volume>101</volume><elocation-id>326</elocation-id><pub-id pub-id-type="doi">10.1002/cpt.503</pub-id><pub-id pub-id-type="pmid">27617708</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>HB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complex versus simple models: ion-channel cardiac toxicity prediction</article-title><source>PeerJ</source><volume>6</volume><elocation-id>e4352</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.4352</pub-id><pub-id pub-id-type="pmid">29423349</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>HB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive in vitro proarrhythmic assay complexity bias</article-title><source>Clinical Pharmacology and Therapeutics</source><volume>105</volume><fpage>1323</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1002/cpt.1400</pub-id><pub-id pub-id-type="pmid">30903693</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morotti</surname><given-names>S</given-names></name><name><surname>Grandi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Logistic regression analysis of populations of electrophysiological models to assess proarrythmic risk</article-title><source>MethodsX</source><volume>4</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.mex.2016.12.002</pub-id><pub-id pub-id-type="pmid">28116246</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>H</given-names></name><name><surname>Morotti</surname><given-names>S</given-names></name><name><surname>Grandi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A heart for diversity: simulating variability in cardiac arrhythmia research</article-title><source>Frontiers in Physiology</source><volume>9</volume><elocation-id>958</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2018.00958</pub-id><pub-id pub-id-type="pmid">30079031</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Hara</surname><given-names>T</given-names></name><name><surname>Virág</surname><given-names>L</given-names></name><name><surname>Varró</surname><given-names>A</given-names></name><name><surname>Rudy</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation</article-title><source>PLOS Computational Biology</source><volume>7</volume><elocation-id>e1002061</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002061</pub-id><pub-id pub-id-type="pmid">21637795</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passini</surname><given-names>E</given-names></name><name><surname>Britton</surname><given-names>OJ</given-names></name><name><surname>Lu</surname><given-names>HR</given-names></name><name><surname>Rohrbacher</surname><given-names>J</given-names></name><name><surname>Hermans</surname><given-names>AN</given-names></name><name><surname>Gallacher</surname><given-names>DJ</given-names></name><name><surname>Greig</surname><given-names>RJH</given-names></name><name><surname>Bueno-Orovio</surname><given-names>A</given-names></name><name><surname>Rodriguez</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human <italic>In Silico</italic> drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity</article-title><source>Frontiers in Physiology</source><volume>8</volume><elocation-id>668</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2017.00668</pub-id><pub-id pub-id-type="pmid">28955244</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugsley</surname><given-names>MK</given-names></name><name><surname>Authier</surname><given-names>S</given-names></name><name><surname>Curtis</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Principles of safety pharmacology</article-title><source>British Journal of Pharmacology</source><volume>154</volume><fpage>1382</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.280</pub-id><pub-id pub-id-type="pmid">18604233</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadrieh</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>SA</given-names></name><name><surname>Subbiah</surname><given-names>RN</given-names></name><name><surname>Domanski</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Quantifying the origins of population variability in cardiac electrical activity through sensitivity analysis of the electrocardiogram</article-title><source>The Journal of Physiology</source><volume>591</volume><fpage>4207</fpage><lpage>4222</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2013.251710</pub-id><pub-id pub-id-type="pmid">23551947</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadrieh</surname><given-names>A</given-names></name><name><surname>Domanski</surname><given-names>L</given-names></name><name><surname>Pitt-Francis</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>SA</given-names></name><name><surname>Hodkinson</surname><given-names>EC</given-names></name><name><surname>Ng</surname><given-names>CA</given-names></name><name><surname>Perry</surname><given-names>MD</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name><name><surname>Gavaghan</surname><given-names>D</given-names></name><name><surname>Subbiah</surname><given-names>RN</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Multiscale cardiac modelling reveals the origins of notched T waves in long QT syndrome type 2</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5069</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6069</pub-id><pub-id pub-id-type="pmid">25254353</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobie</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Parameter sensitivity analysis in electrophysiological models using multivariable regression</article-title><source>Biophysical Journal</source><volume>96</volume><fpage>1264</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2008.10.056</pub-id><pub-id pub-id-type="pmid">19217846</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>TeBay</surname><given-names>C</given-names></name><name><surname>McArthur</surname><given-names>JR</given-names></name><name><surname>Mangala</surname><given-names>M</given-names></name><name><surname>Kerr</surname><given-names>N</given-names></name><name><surname>Heitmann</surname><given-names>S</given-names></name><name><surname>Perry</surname><given-names>MD</given-names></name><name><surname>Windley</surname><given-names>MJ</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation</article-title><source>British Journal of Pharmacology</source><volume>179</volume><fpage>2631</fpage><lpage>2646</lpage><pub-id pub-id-type="doi">10.1111/bph.15757</pub-id><pub-id pub-id-type="pmid">34837219</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varshneya</surname><given-names>M</given-names></name><name><surname>Mei</surname><given-names>X</given-names></name><name><surname>Sobie</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prediction of arrhythmia susceptibility through mathematical modeling and machine learning</article-title><source>PNAS</source><volume>118</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2104019118</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witchel</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Drug-induced hERG block and long QT syndrome</article-title><source>Cardiovascular Therapeutics</source><volume>29</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1111/j.1755-5922.2010.00154.x</pub-id><pub-id pub-id-type="pmid">20406244</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Woosley</surname><given-names>RL</given-names></name><name><surname>Heise</surname><given-names>CW</given-names></name><name><surname>Gallo</surname><given-names>T</given-names></name><name><surname>Woosley</surname><given-names>D</given-names></name><name><surname>Romero</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Risk categories for drugs that prolong QT and induce Torsade de Pointes (TdP)</article-title><conf-name>AZCERT, Inc. 1457 E. Desert Garden Dr., Tucson, AZ 85718: CredibleMeds</conf-name></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>YG</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Drug induced QT prolongation and torsades de pointes</article-title><source>Heart</source><volume>89</volume><fpage>1363</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1136/heart.89.11.1363</pub-id><pub-id pub-id-type="pmid">14594906</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90027.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Christopher L-H</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Cambridge</institution><country>United Kingdom</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>compelling</bold> and novel mathematical method assesses drug pro-arrhythmic cardiotoxicity by examining the electrophysiology of untreated cardiac cells. It will be <bold>valuable</bold> for future drug safety design.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90027.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Heitmann et al introduce a novel method for predicting the potential of drug candidates to cause Torsades de Pointes using simulations. Despite the fact that a multitude of such methods have been proposed in the past decade, this approach manages to provide novelty in a way that is potentially paradigm-shifting. The figures are beautiful and manage to convey difficult concepts intuitively.</p><p>Strengths:</p><p>(1) Novel combination of detailed mechanistic simulations with rigorous statistical modeling</p><p>(2) A method for predicting drug safety that can be used during drug development</p><p>(3) A clear explication of difficult concepts.</p><p>Weaknesses:</p><p>(1) In this reviewer's opinion, the most important scientific issue that can be addressed is the fact that when a drug blocks multiple channels, it is not only the IC50 but also the Hill coefficient that can differ. By the same token, two drugs that block the same channel may have identical IC50s but different Hill coefficients. This is important to consider since concentration-dependence is an important part of the results presented here. If the Hill coefficients were to be significantly different, the concentration-dependent curves shown in Figure 6 could look very different.</p><p>(2) The curved lines shown in Figure 6 can initially be difficult to comprehend, especially when all the previous presentations emphasized linearity. But a further issue is obscured in these plots, which is the fact that they show a two-dimensional projection of a 4-dimensional space. Some of the drugs might hit the channels that are not shown (INaL &amp; IKs), whereas others will not. It is unclear, and unaddressed in the manuscript, how differences in the &quot;hidden channels&quot; will influence the shapes of these curves. An example, or at least some verbal description, could be very helpful.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90027.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In the paper from Hartman, Vandenberg, and Hill entitled &quot;assessing drug safety, by identifying the access of arrhythmia and cardio, myocytes, electro physiology&quot;, the authors, define a new metric, the axis of arrhythmia&quot; that essentially describes the parameter space of ion channel conductance combinations, where early after depolarization can be observed.</p><p>Strengths:</p><p>There is an elegance to the way the authors have communicated the scoring system. The method is potentially useful because of its simplicity, accessibility, and ease of use. I do think it adds to the field for this reason - a number of existing methods are overly complex and unwieldy and not necessarily better than the simple parameter regime scan presented here.</p><p>Weaknesses:</p><p>The method described in the manuscript suffers from a number of weaknesses that plague current screening methods. Included in these are the data quality and selection used to inform the drug-blocking profile. It's well known that drug measurements vary widely, depending on the measurement conditions.</p><p>There doesn't seem to be any consideration of pacing frequency, which is an important consideration for arrhythmia triggers, resulting from repolarization abnormalities, but also depolarization abnormalities. Extremely high doses of drugs are used to assess the population risk. But does the method yield important information when realistic drug concentrations are used? In the discussion, the comparison to conventional approaches suggests that the presented method isn't necessarily better than conventional methods.</p><p>In conclusion, I have struggled to grasp the exceptional novelty of the new metric as presented, especially when considering that the badly needed future state must include a component of precision medicine.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90027.3.sa3</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heitmann</surname><given-names>Stewart</given-names></name><role specific-use="author">Author</role><aff><institution>Victor Chang Cardiac Research Institute</institution><addr-line><named-content content-type="city">Darlinghurst</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Vandenberg</surname><given-names>Jamie I</given-names></name><role specific-use="author">Author</role><aff><institution>Victor Chang Cardiac Research Institute</institution><addr-line><named-content content-type="city">Darlinghurst</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Adam P</given-names></name><role specific-use="author">Author</role><aff><institution>Victor Chang Cardiac Research Institute</institution><addr-line><named-content content-type="city">Darlinghurst</named-content></addr-line><country>Australia</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>Heitmann et al introduce a novel method for predicting the potential of drug candidates to cause Torsades de Pointes using simulations. Despite the fact that a multitude of such methods have been proposed in the past decade, this approach manages to provide novelty in a way that is potentially paradigm-shifting. The figures are beautiful and manage to convey difficult concepts intuitively.</p><p>Strengths:</p><p>(1) Novel combination of detailed mechanistic simulations with rigorous statistical modeling</p><p>(2) A method for predicting drug safety that can be used during drug development (3) A clear explication of difficult concepts.</p><p>Weaknesses:</p><p>(1) In this reviewer's opinion, the most important scientific issue that can be addressed is the fact that when a drug blocks multiple channels, it is not only the IC50 but also the Hill coefficient that can differ. By the same token, two drugs that block the same channel may have identical IC50s but different Hill coefficients. This is important to consider since concentration-dependence is an important part of the results presented here. If the Hill coefficients were to be significantly different, the concentration- dependent curves shown in Figure 6 could look very different.</p></disp-quote><p>See our response below.</p><disp-quote content-type="editor-comment"><p>(2) The curved lines shown in Figure 6 can initially be difficult to comprehend, especially when all the previous presentations emphasized linearity. But a further issue is obscured in these plots, which is the fact that they show a two-dimensional projection of a 4dimensional space. Some of the drugs might hit the channels that are not shown (INaL &amp; IKs), whereas others will not. It is unclear, and unaddressed in the manuscript, how differences in the &quot;hidden channels&quot; will influence the shapes of these curves. An example, or at least some verbal description, could be very helpful.</p></disp-quote><p>See our response below.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>The manuscript is generally well-written (with one important exception, see below). The manuscript can be improved with a few suggested modifications, ordered from most important to least important.</p><p>(1) In this reviewer's opinion, the most important scientific issue that the authors need to address is the fact that when a drug blocks multiple channels, it is not only the IC50 but also the Hill coefficient that can differ. By the same token, two drugs that block the same channel may have identical IC50s but different Hill coefficients. This is important to consider since concentration-dependence is an important part of the results presented here.</p><p>In a recent study (Varshneya et al, CPT PSP 2021 (PMID: 33205613)) they originally ran simulations with Hill coefficients of 1 for all the 4 drugs and 7 channels, then re-ran the simulations with differing Hill coefficients. The results were quantitatively quite different than what was originally obtained, even though the overall trends were identical. A look at the table provided in that paper's supplement shows that the estimated Hill coefficients range from 0.5 to 1.9, which is a pretty wide range.</p><p>In this case, I don't think the authors should re-run the entire analysis. That would require entirely too much work and potentially detract from the elegant presentation of the manuscript in its current form. Although I haven't looked at the Llopis-Lorente dataset recently, I doubt that reliable Hill coefficients have been obtained for all 105 drugs. However, the Crumb et al dataset (PMID: 27060526) does provide this information for 30 drugs.</p><p>Perhaps the authors could choose an example of two drugs that affect similar channels but with differences in the estimated Hill coefficients. Or even a carefully-designed hypothetical example could be of value. At the very least, Hill coefficients need to be mentioned as a limitation, but this would be stronger if it were coupled with at least some novel analyses.</p></disp-quote><p>We fixed the Hill coefficients to h=1 because there is no evidence for co-operative drug binding in the literature that would require coefficients other than one. There is also the practical matter that only 17 of the 109 drugs in the dataset have a complete set of Hill coefficients. We have revised the Methods (Drug datasets) to make these justifications explicit:</p><p>Lines 560-566: “… We also fixed the Hill coefficients at h = 1 because (i) there is no evidence for co-operative drug binding in the literature, and thus no theoretical justification for using coefficients other than one; (ii) only 17 of the 109 drugs in the dataset had a complete set of Hill coefficients (hCaL, hKr, hNaL, hKs) anyway. …”</p><p>Out of interest, we re-ran our analysis using only those n=17 drugs (Amiodarone,Amitriptyline, Bepridil, Chlorpromazine, Diltiazem, Dofetilide, Flecainide, Mibefradil,Moxifloxacin, Nilotinib, Ondansetron, Quinidine, Quinine, Ranolazine, Saquinavir, Terfenadine and Verapamil). When the Hill coefficients were fixed at h=1, the prediction accuracy was 88.2% irrespective of the dosage (Author response image 1). When we used the estimated (free) Hill coefficients, the prediction accuracy remained unchanged (88.2%) for all doses except the lowest (1x to 2x) where it dropped to 82.4%. We concluded that using the Hill coefficients from the dataset made little difference to the results.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(2) I initially had a hard time understanding the curved lines shown in Figure 6 when all the previous presentations emphasized linearity. After thinking for a while, I was able to get it, but there was a further issue that I still struggle with. That is the fact that the plots all show a two-dimensional projection of a 4-dimensional space. Some of the drugs might hit the channels that are not shown (INaL &amp; IKs), whereas others will not. How will differences in the &quot;hidden channels&quot; influence the shapes of these curves? An example, or at least some verbal description, could be very helpful.</p></disp-quote><p>We omitted GKs and GNaL from Figure 6 because they added little to the story. Those “hidden” channels operate in the same manner as GKr and GNaL. They are shown in Supplementary Dataset S1. We have included more explicit references to the Supplementary in both the main text and the caption of Figure 6. We have also rewritten the section on ‘The effect of dosage on multi-channel block’ (lines 249-268) to better convey that the drug acts in four dimensions.</p><disp-quote content-type="editor-comment"><p>(3) I also struggled a bit with Figure 3 and the section &quot;Drug risk metric.&quot; What made this confusing was the PQR notation on the figure and the equations represented as A and B. Can these be presented in a common notation, or can the relationship be defined?</p></disp-quote><p>We have replaced the PQR notation in Figure 3A with vector notation A and B to be consistent with the equations.</p><disp-quote content-type="editor-comment"><p>Also in Figure 3B, I was unclear about the units on the x-axis. Is each step (e.g. from 0 to 1) the same distance as a single log unit along the abscissa or ordinate in Figure 3A?</p></disp-quote><p>Yes it is. We have revised the caption for Figure 3B to explain it better.</p><disp-quote content-type="editor-comment"><p>(4) The manuscript manages to explain difficult concepts clearly, and it is generally wellwritten. The important exception, however, is that the manuscript contains far too many sentence fragments. These often occur when the authors explain a difficult concept, then follow up with something that is essentially &quot;and this in addition&quot; or &quot;with the exception of this.&quot;</p><p>Lines 220-223: &quot;In comparison, Linezolid is an antibacterial agent that has no clinical evidence of Torsades (Class 4) even though it too blocks IKr. Albeit less than it blocks ICaL (Figure 5A, right).&quot;</p><p>Lines 242-245: &quot;Conversely, Linezolid shifts the population 1.18 units away from the ectopic regime. So only 0.0095% of those who received Linezolid would be susceptible. A substantial drop from the baseline rate of 0.93%.&quot;</p><p>There are several others that I didn't note, so the authors should perform a careful copy edit of the entire manuscript.</p></disp-quote><p>Thank you. We have remediated the fragmented sentences throughout.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>In the paper from Hartman, Vandenberg, and Hill entitled &quot;assessing drug safety, by identifying the access of arrhythmia and cardio, myocytes, electro physiology&quot;, the authors, define a new metric, the axis of arrhythmia&quot; that essentially describes the parameter space of ion channel conductance combinations, where early after depolarization can be observed.</p><p>Strengths:</p><p>There is an elegance to the way the authors have communicated the scoring system. The method is potentially useful because of its simplicity, accessibility, and ease of use. I do think it adds to the field for this reason - a number of existing methods are overly complex and unwieldy and not necessarily better than the simple parameter regime scan presented here.</p><p>Weaknesses:</p><p>The method described in the manuscript suffers from a number of weaknesses that plague current screening methods. Included in these are the data quality and selection used to inform the drug-blocking profile. It's well known that drug measurements vary widely, depending on the measurement conditions.</p></disp-quote><p>We agree and have added a new section to describe these limitations, as follows:</p><p>Lines 467-478: Limitations. The method was evaluated using a dataset of drugs that were drawn from multiple sources and diverse experimental conditions (LlopisLorente et al., 2020). It is known that such measurements differ prominently between laboratories and recording platforms (Kramer et al., 2020). Some drugs in the dataset combined measurements from disparate experiments while others had missing values. Of all the drugs in the dataset, only 17 had a complete set of IC50 values for ICaL, IKr, INaL and IKs. The accuracy of the predictions are therefore limited by the quality of the drug potency measurements.</p><disp-quote content-type="editor-comment"><p>There doesn't seem to be any consideration of pacing frequency, which is an important consideration for arrhythmia triggers, resulting from repolarization abnormalities, but also depolarization abnormalities.</p></disp-quote><p>It is true that we did not consider the effect of pacing frequency. We have included this in the limitations:</p><p>Lines 479-485: The accuracy of the axis of arrhythmia is likewise limited by the quality of the biophysical model from which it is derived. The present study only investigated one particular variant of the ORd model (O’Hara et al., 2011; KroghMadsen et al., 2017) paced at 1 Hz. Other models and pacing rates are likely to produce differing estimates of the axis.</p><disp-quote content-type="editor-comment"><p>Extremely high doses of drugs are used to assess the population risk. But does the method yield important information when realistic drug concentrations are used?</p></disp-quote><p>Yes it does. The drugs were assessed across a range of doses from 1x to 32x therapeutic dose (Figure 8A). The prediction accuracy at low doses is 88.1%.</p><disp-quote content-type="editor-comment"><p>In the discussion, the comparison to conventional approaches suggests that the presented method isn't necessarily better than conventional methods.</p></disp-quote><p>The comparison is not just about accuracy. Our method achieves the same results at greatly reduced computational cost without loss of biophysical interpretation. We emphasise this in the Conclusion:</p><p>Lines 446-465: Conclusion. Our approach resolves the debate between model complexity and biophysical realism by combining both approaches into the same enterprise. Complex biophysical models were used to identify the relationship between ion channels and torsadogenic risk — as it is best understood by theory. Those findings were then reduced to a simpler linear model that can be applied to novel drugs without recapitulating the complex computer simulations. The reduced model retains a bio-physical description of multi-channel drug block, but only as far as necessary to predict the likelihood of early after-depolarizations. It does not reproduce the action potential itself. Our approach thus represents a convergence of biophysical and simple models which retains the essential biophysics while discarding the unnecessary details. We believe the benefits of this approach will accelerate the adoption of computational assays in safety pharmacology and ultimately reduce the burden of animal testing.</p><disp-quote content-type="editor-comment"><p>In conclusion, I have struggled to grasp the exceptional novelty of the new metric as presented, especially when considering that the badly needed future state must include a component of precision medicine.</p></disp-quote><p>Safety pharmacology has a different aim to precision medicine. The former concerns the population whereas the latter concerns the individual. The novelty of our metric lies in reducing the complexity of multi-channel drug effects to a linear model that retains a biophysical interpretation.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>A large majority of drugs have more complex effects than a simple reduction and channel conductance. Some of these are included in the 109 drugs shown in Figure 7. An example is ranolazine, which is well known to have potent late sodium channel blocking effects - how are such effects included in the model as presented? I think at least suggesting how the approach can be expanded for broader applicability would be important to discuss.</p></disp-quote><p>Our method does consider the simultaneous effect of the drug on multiple ion channels, specifically the L-type calcium current (ICaL), the delayed rectifier potassium currents (IKr and IKs), and the late sodium current (INaL). In the case of ranolazine (class 3 risk), the dose-responses for all four ion channels, based on IC50s published in Llopis-Lorente et al. are given in Supplementary Dataset S1.</p><p>The response curves in Author response image 2 show that in this dataset, ranolazine blocks IKr and INaL almost equally - being only slightly less potent against IKr. There are two issues to consider here that potentially contribute to ranolazine being misclassified as pro-arrhythmic. First, the cell model is more sensitive to block of IKr than INaL. As a result, in the context of an equipotent drug, the prolonging effect of IKr block outweighs the balancing effect of INaL block, resulting in a pro-arrhythmic risk score. Second, the potency of IKr block in this dataset may be overestimated which in turn exaggerates the risk score. For example, measurements of ranolazine block of IKr from our own laboratory (Windley et al J Pharmacol Toxicol 87, 99–107, 2017) suggest that the IC50 of IKr is higher (35700 nM) than that reported in the LlopisLorente dataset (12000 nM). If this were taken into account, there would be less block of IKr relative to INaL, resulting in a safer risk score.</p><fig id="sa3fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90027-sa3-fig2-v1.tif"/></fig></body></sub-article></article>